| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/12/2002 | EP1212403A1 Method for treatment of beta-hemoglobinopathies |
| 06/12/2002 | EP1212366A2 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 06/12/2002 | EP1212364A1 MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION |
| 06/12/2002 | EP1212363A2 Il-16 antagonists |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212361A1 Preparation of highly pure toxin fragments |
| 06/12/2002 | EP1212359A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212354A2 Ovarian tumor sequences and methods of use therefor |
| 06/12/2002 | EP1212353A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf) |
| 06/12/2002 | EP1212352A1 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1 |
| 06/12/2002 | EP1212350A1 A process for the preparation of h-tyr-d-ala-phe(f)-phe-nh 2? |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212343A1 52 human secreted proteins |
| 06/12/2002 | EP1212342A2 18 human secreted proteins |
| 06/12/2002 | EP1212339A1 2'-o-acetamido modified monomers and oligomers |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212312A1 Novel derivatives of flavones, xanthones and coumarins |
| 06/12/2002 | EP1212300A1 Azacycloalkanone serine protease inhibitors |
| 06/12/2002 | EP1212295A1 SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 06/12/2002 | EP1212269A1 Methods for preparing n- (aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds |
| 06/12/2002 | EP1212120A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 06/12/2002 | EP1212106A1 Phospholipid-coated implants |
| 06/12/2002 | EP1212100A2 Delivery system for antidandruff agent |
| 06/12/2002 | EP1212095A2 Process to make a sustained release formulation |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212085A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/12/2002 | EP1212080A2 The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
| 06/12/2002 | EP1212079A1 Topical treatment of streptococcal infections |
| 06/12/2002 | EP1212078A2 Ant-1 as drug target |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212076A2 Stimulation of sperm function |
| 06/12/2002 | EP1212075A1 Peptides capable of modulating the function of cd66 (ceacam) family members |
| 06/12/2002 | EP1212074A1 Hybrid peptides modulate the immune response |
| 06/12/2002 | EP1212068A1 Method of enhancing the efficacy of anti-tumor agents |
| 06/12/2002 | EP1212066A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
| 06/12/2002 | EP1212055A1 Neurotherapeutic composition and method |
| 06/12/2002 | EP1212046A2 Flushable disposable polymeric products |
| 06/12/2002 | EP1212040A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 06/12/2002 | EP1211931A1 A knockout mouse for the tumor suppressor gene anx7 |
| 06/12/2002 | EP1128844A4 Methods for enhancing wound healing |
| 06/12/2002 | EP1061941B1 A pharmaceutical composition containing ezrin mutated on tyrosine 353 |
| 06/12/2002 | EP1056722B1 Bisulfate salt of hiv protease inhibitor |
| 06/12/2002 | EP1056474B1 Affinity markers for human serum albumin |
| 06/12/2002 | EP1044000B1 Combination therapy for the treatment of aids |
| 06/12/2002 | EP1039922B1 Improved interferon polymer conjugates |
| 06/12/2002 | EP0989855A4 Osteoarthritis cartilage regeneration using human mesenchymal stem cells |
| 06/12/2002 | EP0966274B1 Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| 06/12/2002 | EP0941056B1 Sphingomyelinase compositions and use thereof |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0876158B1 Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms |
| 06/12/2002 | EP0841933B1 Bowman-Birk inhibitor compositions for treatment of inflammatory disease |
| 06/12/2002 | EP0822941B1 Monoclonal antibodies against hiv-1 and vaccines made thereof |
| 06/12/2002 | EP0814791B1 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 06/12/2002 | EP0807185B1 Antitumor preparations containing a lipoteichoic acid from steptococcus |
| 06/12/2002 | EP0802800B1 Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| 06/12/2002 | EP0777677B1 Methods of identifying compounds useful for treating autoimmune diseases |
| 06/12/2002 | EP0759774B1 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic |
| 06/12/2002 | EP0749325B1 Bispecific molecules having clinical utilities |
| 06/12/2002 | EP0749317B1 Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
| 06/12/2002 | EP0741576B1 Co-administration of interleukin-3 mutants with colony stimulating factors |
| 06/12/2002 | EP0734391B1 Pna-dna-pna chimeric macromolecules |
| 06/12/2002 | EP0722452B1 Nf-at polypeptides and polynucleotides |
| 06/12/2002 | EP0697881B1 New cyclosporine-containing pharmaceutical compositions for oral administration |
| 06/12/2002 | EP0688211B1 Thalidomide for inhibition of angiogenesis |
| 06/12/2002 | EP0669833B1 Type ii tgf-beta-binding receptor fragment as therapeutic agent |
| 06/12/2002 | EP0666753B9 Use of peptides FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES |
| 06/12/2002 | EP0574395B1 Cytokine immunoconjugates |
| 06/12/2002 | CN1353816A Method for identifying individual at risk for irreversible neurodamages, comprising steps of determining quantatively concentration of pepsinogen I(PGI) and vitamin B12 |
| 06/12/2002 | CN1353754A Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNF alpha) signaling pathway |
| 06/12/2002 | CN1353701A Peptidyl heterocyclic ketones useful as tryptase inhibitors |
| 06/12/2002 | CN1353617A Treatment of infertility |
| 06/12/2002 | CN1353616A New use of substance in PNS |
| 06/12/2002 | CN1353615A Compositions of A-beta peptide and processes for producing same |
| 06/12/2002 | CN1353614A Method of treating chronic cardiac disease |
| 06/12/2002 | CN1353613A Pharmaceutical compositions |
| 06/12/2002 | CN1353573A Anti-inflammatory therapy for inflammatory mediated infection |
| 06/11/2002 | USRE37741 Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection |
| 06/11/2002 | US6404779 System and method of disharmonic frequency multiplexing |
| 06/11/2002 | US6403785 Isolated DNA molecule encoding human TSC403 |
| 06/11/2002 | US6403784 Human uncoupling proteins and polynucleotides encoding the same |
| 06/11/2002 | US6403782 Nucleic acid encoding eotaxin |
| 06/11/2002 | US6403770 Antibodies to neutrokine-alpha |
| 06/11/2002 | US6403769 Fusion protein having nonantibody portion comprised of effector domain from growth factor or growth factor receptor joined to aminoterminal end of immunoglobulin g-derived sequence which lacks ch1 domain |
| 06/11/2002 | US6403767 Polypeptide molecules of the G protein-coupled heptahelical receptor superfamily and uses therefor |
| 06/11/2002 | US6403764 Variant wherein amino acid residue at position 16 of native-sequence human igf-1 is replaced with glycine or serine, or amino acid residue at position 25 or 49 or residues at 3 and 49 are replaced with alanine, glycine, or serine |
| 06/11/2002 | US6403758 Bioresorbable compositions for implantable prostheses |
| 06/11/2002 | US6403609 Topical-use lubricant that gels when administered to the eye |
| 06/11/2002 | US6403564 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 06/11/2002 | US6403562 Materials and methods for treating autoimmune disease |
| 06/11/2002 | US6403561 Disorders associated with the inactivation or excessive degradation of cholecystokinin; inhibiting the enzymatic hydrolysis of cholecystokinin 1-(2(s)-aminobutyryl)-2(s)-indolinecarboxylic acid |
| 06/11/2002 | US6403560 Extracting hyaluronic acid together with a protein from chicken comb, mammalian skin or mammalian organ; |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403558 Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis |
| 06/11/2002 | US6403557 Fibroblast growth factor-13 |
| 06/11/2002 | US6403556 Pharmaceutical preparation containing protein C and a thrombolytically active substance |
| 06/11/2002 | US6403555 Depsipeptide and congeners thereof for use as immunosuppressants |
| 06/11/2002 | US6403553 Induced by chemotherapy, irradiation, or disease; macrophage inflammatory proteins give significant and specific increase of platelet count |
| 06/11/2002 | US6403552 Ob receptor and methods for the diagnosis and treatment of body weight disorders |